GILEAD SCIENCES, INC. is 18.8x more valuable than QIAGEN N.V. by market capitalization ($150.83 B vs $8.03 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | QGEN | GILD |
|---|---|---|
| Market cap | $8.03 B | $150.83 B |
| US-listed rank | #1070 | #99 |
| Revenue (latest FY) | $2.09B | $29.44B |
| Net income (latest FY) | $424.88M | $8.51B |
| Net margin | 20.3% | 28.9% |
| P/E (trailing FY) | 18.9 | 17.7 |
| SEC filings | 471 | 981 |
GILEAD SCIENCES, INC. is 18.8x more valuable than QIAGEN N.V. by market capitalization ($150.83 B vs $8.03 B).
In their latest fiscal years, QIAGEN N.V. reported $2.09B in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: QIAGEN N.V. and GILEAD SCIENCES, INC., or browse the full rankings.